Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Mortality Comparison of Using Anti Interleukin-6 Therapy and Using Standard Treatment in Severe Covid-19

Folia Medica Indonesiana · Vol. 57 No. 2 (2021) · hlm. 158–158

DOI
10.20473/fmi.v57i2.21929
ISSN
2355-8393, 2599-056X
Terbit
2021-06-01
Penerbit
Airlangga University
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0/

Abstrak

Severe Coronavirus Disease 19 (COVID-19) can cause serious lung inflammation and death. COVID-19 is characterized by a high mortality rate. This severity is associated with the overproduction of proinflammatory cytokines called "cytokine storms". One of the cytokines that play a central role is Interleukin-6 (IL-6). High IL-6 levels are associated with mortality. Expectedly, the IL-6 blockade could reduce cytokine storms and thus reduce deaths in severe COVID-19 patients. This systematic review aimed to summarize the comparison between mortality using anti-IL-6 therapy and mortality using standard treatment in severe COVID-19 patients. We systematically searched the PubMed, ScienceDirect, and ProQuest databases until 13 August 2020. After screening, twelve studies matched the inclusion criteria. The mortality of the anti-IL-6 therapy group was lower than the standard treatment group without anti-IL-6 therapy in COVID-19 patients in 10 of the 12 studies obtained. Four of the ten studies statistically found a significant difference in mortality of the anti-IL-6 therapy group and the standard treatment group. Confirmation of anti-IL-6 therapy effectiveness in reducing mortality in severe COVID-19 patients will require randomized controlled trials.

Kata kunci

Jaringan kolaborasi para penulis

24 penulis · 64 tautan kepenulisan bersama · 14 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Airlangga
  • Rumah Sakit Dokter Soetomo
  • University of Technology Malaysia
  • Universitas Pattimura
  • Mulawarman University
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Annette d’ArqomUniversitas Airlangga2
Mhd Zamal NasutionUniversitas Airlangga2
Sri PurwaningsihUniversitas Airlangga1
Yuani SetiawatiUniversitas Airlangga1
Farhan NurdiansyahUniversitas Airlangga1
Nurmawati FatimahUniversitas Airlangga1
Kusuma Eko PurwantariUniversitas Airlangga1
Qonita BajuberUniversitas Airlangga1
Edward KusumaUniversitas Airlangga1
Junaidah YusofUniversity of Technology Malaysia1
Kinesha KostyaUniversitas Airlangga1
Nazwa Febry SaviraUniversitas Airlangga1
Juen Carla WarellaUniversitas Pattimura1
Rebekah Juniati SetiabudiUniversitas Airlangga1
Khairunnida RahmaMulawarman University1
Ahmad Veri EriantoUniversitas Airlangga1
Tri Pudy AsmarawatiRumah Sakit Dokter Soetomo1
Brian Eka RachmanRumah Sakit Dokter Soetomo1
Budi SupraptiUniversitas Airlangga1
Muhammad Thariq NadhafiAfiliasi tidak diketahui1
Bambang WahjuprajitnoAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Mortality Comparison of Using Anti Interleukin-6 Therapy and Using Standard Treatment in Severe Covid-19</dc:title><dc:creator>Jonathan Christianto Sutadji</dc:creator><dc:creator>Agung Dwi Wahyu Widodo</dc:creator><dc:creator>Danti Nur Indiastuti</dc:creator><dc:subject>severe COVID-19</dc:subject><dc:subject>interleukin-6</dc:subject><dc:subject>IL-6 inhibition</dc:subject><dc:subject>cytokine storm</dc:subject><dc:subject>mortality</dc:subject><dc:subject>standard treatment</dc:subject><dc:subject>inflammatory cytokines</dc:subject><dc:subject>lung inflammation</dc:subject><dc:description xml:lang="en">Severe Coronavirus Disease 19 (COVID-19) can cause serious lung inflammation and death. COVID-19 is characterized by a high mortality rate. This severity is associated with the overproduction of proinflammatory cytokines called "cytokine storms". One of the cytokines that play a central role is Interleukin-6 (IL-6). High IL-6 levels are associated with mortality. Expectedly, the IL-6 blockade could reduce cytokine storms and thus reduce deaths in severe COVID-19 patients. This systematic review aimed to summarize the comparison between mortality using anti-IL-6 therapy and mortality using standard treatment in severe COVID-19 patients. We systematically searched the PubMed, ScienceDirect, and ProQuest databases until 13 August 2020. After screening, twelve studies matched the inclusion criteria. The mortality of the anti-IL-6 therapy group was lower than the standard treatment group without anti-IL-6 therapy in COVID-19 patients in 10 of the 12 studies obtained. Four of the ten studies statistically found a significant difference in mortality of the anti-IL-6 therapy group and the standard treatment group. Confirmation of anti-IL-6 therapy effectiveness in reducing mortality in severe COVID-19 patients will require randomized controlled trials.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2021-06-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.20473/fmi.v57i2.21929</dc:identifier><dc:identifier>10.20473/fmi.v57i2.21929</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 57 No 2 (2021); 158-158</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language><dc:relation>https://e-journal.unair.ac.id/FMI/article/download/21929/14938</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc-sa/4.0/</dc:rights></oai_dc:dc>